Free Trial

Genus (LON:GNS) Given New GBX 2,900 Price Target at Deutsche Bank Aktiengesellschaft

Genus logo with Medical background

Key Points

  • Deutsche Bank Aktiengesellschaft raised its price target for Genus (LON:GNS) from GBX 2,550 to GBX 2,900, indicating a potential upside of 11.01% from the previous close.
  • Shore Capital also maintained a "buy" rating and set the same price target of GBX 2,900 for Genus stock, which currently has an average rating of "Buy" among analysts.
  • As of the latest trading day, Genus shares opened at GBX 2,612.27, and the company reported GBX 81.80 EPS in its most recent earnings announcement.
  • Five stocks to consider instead of Genus.

Genus (LON:GNS - Get Free Report) had its price target boosted by equities researchers at Deutsche Bank Aktiengesellschaft from GBX 2,550 to GBX 2,900 in a research note issued to investors on Monday,Digital Look reports. The firm currently has a "buy" rating on the stock. Deutsche Bank Aktiengesellschaft's price objective would indicate a potential upside of 11.01% from the stock's previous close.

Separately, Shore Capital restated a "buy" rating and set a GBX 2,900 price target on shares of Genus in a report on Thursday, September 4th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Genus currently has an average rating of "Buy" and an average price target of GBX 2,900.

Get Our Latest Stock Analysis on Genus

Genus Stock Performance

Shares of GNS stock opened at GBX 2,612.27 on Monday. The company has a market capitalization of £1.72 billion, a price-to-earnings ratio of -42,133.31, a P/E/G ratio of 2.87 and a beta of 0.37. Genus has a 1-year low of GBX 1,424 and a 1-year high of GBX 3,228.80. The company has a current ratio of 1.80, a quick ratio of 1.08 and a debt-to-equity ratio of 53.12. The stock's fifty day simple moving average is GBX 2,511.45 and its 200-day simple moving average is GBX 2,117.43.

Genus (LON:GNS - Get Free Report) last announced its quarterly earnings data on Thursday, September 4th. The company reported GBX 81.80 earnings per share (EPS) for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. On average, sell-side analysts predict that Genus will post 70.9644323 earnings per share for the current fiscal year.

Genus Company Profile

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Genus Right Now?

Before you consider Genus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.

While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.